SCHEMBL469265

SCHEMBL469265

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(C)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.55
MAPT P10636 4/20 0.55
CYP19A1 P11511 4/20 0.55
PPARG P37231 3/20 0.55
OXER1 Q8TDS5 3/20 0.55
RXRA P19793 2/20 0.55
FFAR1 O14842 2/20 0.55
F7 P08709 3/20 0.52
F3 P13726 3/20 0.52
PPARA Q07869 3/20 0.52
PTGS1 P23219 3/20 0.52
KMT2A Q03164 2/20 0.52
PPARD Q03181 2/20 0.52
ADORA3 P0DMS8 1/20 0.52
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
NR1I2 O75469 1/20 0.49
LMNA P02545 1/20 0.49
PLA2G1B P04054 1/20 0.49
CYP3A4 P08684 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14767921 1.00 ALDH1A1 (0.55) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL14767922 1.00 ALDH1A1 (0.55) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL892782 0.95 ALDH1A1 (0.57) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL892781 0.95 ALDH1A1 (0.57) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL5774607 0.94 GABRR1 (0.46) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL5586095 0.94 GABRR1 (0.46) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL5586091 0.94 GABRR1 (0.46) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL29619483 0.89 ALDH1A1 (0.58) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL3224652 0.87 ALDH1A1 (0.57) ALDH1A1MAPTCYP19A1PPARGOXER1
SCHEMBL20553456 0.86 ALDH1A1 (0.60) ALDH1A1MAPTCYP19A1PPARGOXER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2010508259-A 2010-03-18 JP claimed
US-20100035990-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) PRONOVA BIOPHARMA NORGE AS (NO) 2010-02-11 US claimed
EP-2094640-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). Pronova BioPharma Norge AS (NO) 2009-09-02 EP claimed
WO-2008053331-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). PRONOVA BIOPHARMA NORGE A/S (SE) 2008-05-08 WO claimed
EP-3383380-B1 LIPID COMPOUNDS AND COMPOSITIONS AND THEIR OPTHALMIC USE BIOZEP AS (NO) 2023-01-04 EP disclosed
US-8399516-B2 Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR) PRONOVA BIOPHARMA NORGE AS (NO) 2013-03-19 US disclosed
US-20120065260-A1 NOVEL COMPOUNDS Pronova BioPhrma Norge AS 2012-03-15 US disclosed
US-8034842-B2 Compounds PRONOVA BIOPHARMA NORGE AS (NO) 2011-10-11 US disclosed
US-20100267828-A1 DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS PRONOVA BIOPHARMA NORGE AS (NO) 2010-10-21 US disclosed
US-20100035990-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) PRONOVA BIOPHARMA NORGE AS (NO) 2010-02-11 US disclosed
EP-2094640-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). Pronova BioPharma Norge AS (NO) 2009-09-02 EP disclosed
US-20090203778-A1 FATTY ACID ANALOGUES, I.E. INCLUDING DHA DERIVATIVES FOR USES AS A MEDICAMENT PRONOVA BIOPHARMA NORGE AS (NO) 2009-08-13 US disclosed
US-7550613-B2 alpha-methoxy docosahexanoic acid ethyl ester, alpha-iodo-docosahexanoic acid ethyl ester; antidiabetic for diabetes type 2, cardiovascular disorders, obesity, amyloidosis, prophylaxis; free of 4,7,10,13,16,19-docosahexanoic acid ( DHA), alpha-methyl DHA, alpha-methyl DHA-methyl ester PRONOVA BIOPHARMA NORGE AS (NO) 2009-06-23 US disclosed
US-20080300306-A1 Novel Compounds BRYHN MORTEN 2008-12-04 US disclosed
WO-2008053340-A1 A COMBINATION PRODUCT COMPRISING AT LEAST ONE LIPID SUBSTITUTED IN THE ALPHA POSITION AND AT LEAST ONE HYPOGLYCEMIC AGENT PRONOVA BIOPHARMA NORGE AS (NO) 2008-05-08 WO disclosed
WO-2008053331-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). PRONOVA BIOPHARMA NORGE A/S (SE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035990-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) PPARG, PPARA, FFAR3 ALDH1A1 1088/4885MAPT 4860/4885CYP19A1 922/4885
US-20090203778-A1 FATTY ACID ANALOGUES, I.E. INCLUDING DHA DERIVATIVES FOR USES AS A MEDICAMENT ALOX12, ALOX15, ALOX5 ALDH1A1 611/4885MAPT 933/4885CYP19A1 812/4885
US-20100267828-A1 DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS LIPA, LPL, PNLIP ALDH1A1 1114/4885MAPT 4554/4885CYP19A1 1358/4885
US-20080300306-A1 Novel Compounds GPR119, FFAR2, ALOX12 ALDH1A1 868/4885MAPT 4615/4885CYP19A1 879/4885
US-20120065260-A1 NOVEL COMPOUNDS FFAR2, GPR119, ALOX12 ALDH1A1 911/4885MAPT 4633/4885CYP19A1 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.